Table 1.

Targeted therapies for lung cancer.

Target	Alteration	Frequency	Targeted Agent	Status
EGFR-sensitizing	Mutation	17%	(First generation EGFR-TKIs)
			Gefitinib	Approved by FDA
			Erlotinib	Approved by FDA
			(Second generation EGFR-TKIs)
			Afatinib	Approved by FDA
			Dacomitinib	Approved by FDA
			(Third generation EGFR-TKIs)
			Osimertinib	Approved by FDA
ALK	Rearrangement	7%	(First generation ALK-TKIs)
			Crizotinib	Approved by FDA
			(Second generation ALK-TKIs)
			Alectinib	Approved by FDA
			Ceritinib	Approved by FDA
			Brigatinib	Approved by FDA
			(Third generation ALK-TKIs)
			Lorlatinib	Approved by FDA
MET	Alteration	3%	Tepotinib	Approved by FDA
			Capmatinib	Approved by FDA
			Crizotinib	Phase II
			Cabozantinib	Phase II
ROS1	Rearrangement	2%	Crizotinib	Approved by FDA
			Entrectinib	Approved by FDA
			Ceritinib	Phase II
			Lorlatinib	Phase II
			Repotrectinib	Phase I/II
			Taletrectinib	Phase II
BRAF	Mutation	1–5%	Dabrafenib (with Trametinib)	Approved by FDA
			Vemurafenib	Phase II/III
RET	Rearrangement	1–2%	Selpercatinib	Approved by FDA
			Pralsetinib	Approved by FDA
			Cabozantinib	Phase II